Inositol hexaphosphate suppresses growth and induces apoptosis in HT-29 colorectal cancer cells in culture: PI3K/Akt pathway as a potential target

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1402-1410

  Liu, Guiyuan ^a   Song, Yang ^a   Cui, Lianhua ^a   Wen, Zhaoxia ^a   Lu, Xiaoqing ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; HT 29; Human colorectal cancer cell; Inositol hexaphosphate; PI3K Akt pathway

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHYTIC ACID; PROTEIN KINASE B;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECTS; HT-29 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PHYTIC ACID; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84928150215     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol 2005; 6: 871-876.
3. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-780.
4. Bakewell S. Phytic acid: a phytochemical with complementary and alternative benefits. Cancer Biol Ther 2006; 5: 1134-1135.
5. Shamsuddin AM, Wah A. Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis 1989; 10: 625-626.
6. Vucenik I, Yang GY, Shamsuddin AM. Inositol hexaphosphate and inositol inhibits DMBA-induced rat mammary cancer. Carcinogenesis 1995; 16: 1055-1058.
7. Fox CH, Eberl M. Phytic acid (IP6), novel broad-spectrum anti-neoplastic agent: a systematic review. Complement Ther Med 2002; 10: 229-234.
8. Bakewell S. Phytic acid: a phytochemical with complementary and alternative benefits. Cancer Biol Ther 2006; 5: 1134-1135.
9. Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositol. Nutr Cancer 2006; 55: 109-125.
10. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 2003; 133: 3778S-3784S.
11. Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositol. Nutr Cancer 2006; 55: 109-125.
12. Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II. Effects on integrins and focal adhesions. Anticancer Res 2003; 23: 3681-3689.
13. Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agent. Life Sci 1977; 61: 343-554.
14. Yang GY, Shamsuddin AM. IP6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates. Anticancer Res 1995; 15: 2479-2487.
15. Shamsuddin AM, Yang GY, Vucenik I. Novel anti-cancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 1996; 16: 3287-3292.
16. Vucenik I, Passanti A, Vitolo MI, Tantivejkul K, Eggleton P, Shamsuddin AM. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 2004; 25: 2115-2123.
17. Shamsuddin AM, Yang GY, Vucenik I. Novel anticancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines. Anticancer Res 1996; 16: 3287-3292.
18. Shamsuddin AM, Said IT. Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. Anticancer Res 1998; 18: 1479-1484.
19. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 2000; 21: 2225-2235.
20. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol hexaphosphate inhibits constitutive activation of NF-kappa B in androgen-independent human prostate carcinoma DU145 cells. Anticancer Res 2003; 23: 3855-3861.
21. Shafie NH, Esa NM, Ithnin H, Saad H, Pandurangan AK. Pro-apoptotic effect of rice braninositol hexaphosphate (IP6) on HT-29 colorectal cancer cells. Int J Mol Sci 2013; 14: 23545-23558.
22. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM. Novel Expression Patterns of PI3K/AKT/mTOR Signaling Pathway. J Am Coll Surg 2010; 210: 767-778.
23. Ma BB, Bristow RG, Kim J and Siu LL. Combined- modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003; 21: 2760-2776.
24. Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL, Zempolich KA. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 2006; 12: 250-256.
25. Shaw RJ, Cantley LC. PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
26. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-267.
27. Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. Chem Med Chem 2008; 3: 1810-1838.
28. Gurumurthy S, Vasudevan KM, Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001; 20: 225-243.
29. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-885.
30. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostatecancer. J Cell Biochem 2004; 91: 70-99.
31. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
32. Ferry S, Matsuda M, Yoshida H, Hirata M. Inositol hexaphosphate blocks tumor cell growth by activating apoptotic machinery as well as inhibiting the Akt/NFκB-mediated cell survival pathway. Carcinogenesis 2002; 23: 2031-2041.
33. Verghese M, Rao DR, Chawan CB, Walker LT, Shackelford L. Anticarcinogenic effect of phytic acid (IP6): apoptosis as a possible mechanism of action. LWT- Food Science and Technology 2006; 39: 1093-1098.
34. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 2003; 133: 3778S-3784S.
35. Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositol. Nutr Cancer 2006; 55: 109-125.
36. Gu M, Roy S, Raina K, Agarwal C, Agarwal R. Inositol Hexaphosphate Suppresses Growth and Induces Apoptosis in Prostate Carcinoma Cells in Culture and Nude Mouse Xenograft: PI3K-Akt Pathway as Potential Target. Cancer Res 2009; 69: 9465-9472.
37. Shafie NH, Esa NM, Ithnin H, Saad N, Pandurangan AK. Pro-apoptotic effect of rice bran inositol hexaphosphate (IP6) on HT-29 colorectal cancer cells. Int J Mol Sci 2003; 14: 23545-23558.
38. Xin M, Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005; 280: 10781-10789.
39. Wang XT, Pei DS, Xu J, Guan QH, Sun YF, Liu XM, Zhang GY. Opposing effects of Bad phosphorylation at two distinct sites by Akt1 and JNK1/2 on ischemic brain injury. Cell Signal 2007; 19: 1844-1856.
40. Huang C, Ma WI, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3 kinase. Cancer Res 1997; 57: 2873-2878.
41. Shamsuddin AM, Vucenik I and Cole KE. IP6: A novel anticancer agent. Life Sci 1997; 61: 343-354.
42. Huang C, Ma WY, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. Cancer Res 1997; 57: 2873-2878.
43. Pu P, Kang C, Li J, Jiang H. Antisense and dominantnegative AKT2 cDNA inhibits glioma cell invasion. Tumour Biol 2004; 25: 172-178.
44. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996; 93: 3636-3641.
45. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-609.
46. Ashkenazi A and Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
47. Menniti FS, Oliver KG, Putney JW, Shears SB. Trends Biochem Sci 1993; 18: 53-56.
48. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203-34.